Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
Daratumumab, Bortezomib and Dexamethasone versus Bortezomib and Dexamethasone in RRMM: Efficacy and Safety Update (CASTOR)
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
Researchers from the CASTOR trial provided an update on the efficacy and safety of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).
Read Article
Trends in Survival and Costs Among US Patients with Multiple Myeloma
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
This study examined the trends in survival and healthcare costs of US patients with multiple myeloma from 2006 to 2014.
Read Article
Comparative Efficacy of MM Therapies for Treatment of First Relapse: A Systematic Literature Review and Network Meta-Analysis
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
A systematic literature review and network meta-analysis were conducted to determine the comparative efficacy of multiple myeloma (MM) therapies for treating first relapse.
Read Article
Racial Differences in Abnormalities by FISH in Minorities with Multiple Myeloma: A Single-Center Experience
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
This study provides a closer look at the racial differences in fluorescence in situ hybridization (FISH) abnormalities in minorities with multiple myeloma.
Read Article
Cost-Effectiveness of Carfilzomib, Ixazomib, Elotuzumab, or Daratumumab with Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in RRMM
ASCO 2017 – Multiple Myeloma
,
ASCO
Conference Correspondent
— June 7, 2017
The combination of daratumumab plus lenalidomide and dexamethasone is associated with the greatest progression-free survival life-years and quality-adjusted life-years versus combinations including carfilzomib, ixazomib, and elotuzumab with relapsed/refractory multiple myeloma (RRMM).
Read Article
Plenary Session 2B: Tobacco Control and Smoking Cessation and Prevention
WCLC 2016 – Lung Cancer
Conference Correspondent
— December 1, 2016
Tobacco use is a preventable cause of cancer. Data suggest that approximately 33% of all cancers, including lung, head and neck, esophageal, pancreas, colon, and some types of leukemia, are caused by tobacco use. This session will review the relationships between smoking, free trade, industry regulation, and global public health.
Read Article
Mini Oral Session 1: Improvement and Implementation of Lung Cancer Screening
WCLC 2016 – Lung Cancer
Conference Correspondent
— December 1, 2016
Early detection of lung cancer enhances patient survival. However, the value of specific screening programs is affected by multiple factors, including patient selection methods, triage algorithms, and imaging technology. This oral session includes presentations of novel approaches to the detection of lung cancer.
Read Article
Plenary Session 4A: Advances in Therapy for Metastatic Non–Small-Cell Lung Cancer (NSCLC)
WCLC 2016 – Lung Cancer
Conference Correspondent
— December 1, 2016
This plenary session includes 4 presentations that describe the role of PD-L1 testing and immuno-oncology agents in the treatment of patients with first-line and relapsed NSCLC. All of these abstracts are embargoed until December 7, 2016.
Read Article
Plenary Session 5: Reflections from Giants on Milestones in the Treatment Advances in Lung Cancer—Translational Lung Cancer Research
WCLC 2016 – Lung Cancer
Conference Correspondent
— December 1, 2016
Association of a survival benefit with chemotherapy use for non–small-cell lung cancer (NSCLC) was observed only after the development of cisplatin and platinum doublets. Recent therapeutic advancements in NSCLC and other solid tumors have revolved around the development of immunotherapies that inhibit immune checkpoints, as well as drugs that target driver mutations.
Read Article
First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC (CheckMate 012)
WCLC 2016 – Lung Cancer
Conference Correspondent
— December 1, 2016
Nivolumab, a PD-1 immune checkpoint inhibitor, has demonstrated superior efficacy relative to docetaxel in patients with advanced non–small-cell lung cancer (NSCLC) who progressed on or after platinum-based chemotherapy regardless of PD-L1 expression. Researchers presented findings from a phase 1 study of nivolumab as first-line therapy for advanced NSCLC.
Read Article
Page 17 of 44
12
13
14
15
16
17
18
19
20
21
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma